key: cord-0939706-2xrs6gce
authors: Wu, En-Ling; Kumar, Rebecca N.; Moore, W. Justin; Hall, Gavin T.; Vysniauskaite, Indre; Kim, Kwang-Youn A.; Angarone, Michael P.; Stosor, Valentina; Ison, Michael G.; BBA, Adam Frink; Achenbach, Chad J.; Gates, Khalilah L.
title: Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study
date: 2022-04-25
journal: J Gen Intern Med
DOI: 10.1007/s11606-022-07603-4
sha: 0e9dfdf676c055e32f644a257381298fae7d49a6
doc_id: 939706
cord_uid: 2xrs6gce

BACKGROUND: Disparities in access to anti-SARS-CoV-2 monoclonal antibodies have not been well characterized. OBJECTIVE: We sought to explore the impact of race/ethnicity as a social construct on monoclonal antibody delivery. DESIGN/PATIENTS: Following implementation of a centralized infusion program at a large academic healthcare system, we reviewed a random sample of high-risk ambulatory adult patients with COVID-19 referred for monoclonal antibody therapy. MAIN MEASURES: We examined the relationship between treatment delivery, race/ethnicity, and other demographics using descriptive statistics, binary logistic regression, and spatial analysis. KEY RESULTS: There was no significant difference in racial composition between patients who did (n = 25) and patients who did not (n = 378) decline treatment (p = 0.638). Of patients who did not decline treatment, 64.8% identified as White, 14.8% as Hispanic/Latinx, and 11.1% as Black. Only 44.6% of Hispanic/Latinx and 31.0% of Black patients received treatment compared to 64.1% of White patients (OR 0.45, 95% CI 0.25–0.81, p = 0.008, and OR 0.25, 95% CI 0.12–0.50, p < 0.001, respectively). In multivariable analysis including age, race, insurance status, non-English primary language, county Social Vulnerability Index, illness severity, and total number of comorbidities, associations between receiving treatment and Hispanic/Latinx or Black race were no longer statistically significant (AOR 1.32, 95% CI 0.69–2.53, p = 0.400, and AOR 1.34, 95% CI 0.64–2.80, p = 0.439, respectively). However, patients who were uninsured or whose primary language was not English were less likely to receive treatment (AOR 0.16, 95% CI 0.03–0.88, p = 0.035, and AOR 0.37, 95% CI 0.15–0.90, p = 0.028, respectively). Spatial analysis suggested decreased monoclonal antibody delivery to Cook County patients residing in socially vulnerable communities. CONCLUSIONS: High-risk ambulatory patients with COVID-19 who identified as Hispanic/Latinx or Black were less likely to receive monoclonal antibody therapy in univariate analysis, a finding not explained by patient refusal. Multivariable and spatial analyses suggested insurance status, language, and social vulnerability contributed to racial disparities. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07603-4.

To date, the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the following anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies to use in mild to moderate coronavirus disease 2019 : bamlanivimab (LY-CoV555, Eli Lilly), bamlanivimab (LY-CoV555, Eli Lilly)/ etesevimab (LY-CoV016, Eli Lilly), casirivimab (REGN10933, Regeneron)/imdevimab (REGN10987, Regeneron), sotrovimab (VIR-7831, GlaxoSmithKline/Vir Technology), and bebtelovimab (LY-CoV1404, Eli Lilly) . 1-3 (Due to resistance in circulating variants, access is currently limited to bebtelovimab.) Monoclonal antibodies have been associated with decreased viral load, hospitalization, and mortality in high-risk ambulatory patients. [4] [5] [6] [7] [8] [9] [10] Prior to increased demand in response to rising Delta and then Omicron variant infections (as well as vaccine misinformation and hesitancy), monoclonal antibodies had been underutilized due to low referral rates and limited healthcare capacity for ambulatory infusions including space and staffing. [11] [12] [13] [14] Local access to monoclonal antibodies in underserved communities has not been well characterized.

Between October 2020 and January 2021, the federal government purchased 950,000 doses of bamlanivimab (modified later to include etesevimab) and over 2.9 million doses of casirivimab/imdevimab. [15] [16] [17] By March 2, 2021, it had allocated 946,613 and delivered 761,614 doses of monoclonal antibodies. 18 Under the U.S. Department of Health and Human Services (HHS) Special Projects for Equitable and Efficient Distribution (SPEED), 30,000 doses were allocated and distributed to underserved communities via dialysis centers, federally qualified health centers, long-term care facility pharmacies, home infusion providers, and correction facilities. 19 With the suspension of federal allocation from February 2021 to September 13, 2021 , during which providers ordered directly from the distributor, AmerisourceBergen, SPEED became defunct.

During the COVID-19 pandemic, Black, Hispanic/ Latinx, and American Indian/Alaska Native communities have experienced significantly greater cumulative risk of infection, hospitalization, and death, exacerbating existing health disparities. 20, 21 Race/ethnicity serves as a surrogate for "complex connotations that reflect culture, history, socioeconomics and political status." 22 Aligned with this concept, we use race/ethnicity as a social, not biologic, construct reflecting the impact of structural determinants of health leading to healthcare disparities and, for the purposes of this study, focus on disparities associated with racial segregation at the neighborhood population level. Chicago is one of the most racially segregated metropolitan areas in the U.S.A. (Appendix Figure 5) , with corresponding gaps in life expectancy, COVID-19 infection, and other health outcomes between its Central/North Side and West/South Side regions. 23 When exploring this relationship, the Social Vulnerability Index (SVI) is often used as a more holistic descriptor of populations at risk for disparities during emergency health crises. SVI utilizes U.S. Census data to identify vulnerable communities based on factors affecting socioeconomic status, household composition/disability, minority status/language, and housing/transportation (Appendix Figure 6 ). 24 SVI has been associated with COVID-19 incidence and mortality. [25] [26] [27] In our initial analysis of bamlanivimab use to prevent hospitalization in high-risk ambulatory patients with COVID-19, we noted that Black and Hispanic/Latinx patients were less likely than White patients to receive monoclonal antibodies, 7 a finding since reproduced in single-center and national retrospective studies. 28, 29 Another study reported that non-Hispanic White patients were more likely to accept monoclonal antibodies. 30 In this study, we examine the impact of race/ ethnicity as a social construct on monoclonal antibody delivery to high-risk ambulatory patients with COVID-19.

In the midst of the second wave of the pandemic in Illinois, our healthcare system, which comprises 10 hospitals and over 200 inpatient and outpatient sites in the greater Chicago, Illinois, area, initiated monoclonal antibody administration on November 20, 2020, using an electronic health record (EHR)-based referral order process. At the time of study, bamlanivimab was the only monoclonal antibody available in our system; its EUA was subsequently revoked due to the development of resistant variants. 31, 32 The ordering clinician was expected to provide informed consent using EUA patient information available in English and Spanish. Using over-the-phone interpretation as needed, a centralized call team made three attempts to reach each patient and scheduled appointments at designated outpatient infusion centers. Certain emergency departments were also able to administer treatment to qualifying patients at the time of presentation. Referral orders expired after 10 days. Referral volumes never exceeded capacity.

We reviewed a random selection of patients from the 482 non-canceled referral orders placed November 19, 2020 to January 19, 2021. Ambulatory adult patients were included if they had documented COVID-19, met clinical criteria as high risk or were healthcare workers, and were referred for treatment under EUA. Patients were excluded if they reported more than 14 days of symptoms prior to testing or received infusion at an outside healthcare system. Primary analysis focused on factors associated with monoclonal antibody delivery (defined as documented infusion within 10 days of referral order) in patients who did not explicitly decline treatment per call team notes. A secondary analysis compared patients who did and did not decline treatment. Additional data extracted from the EHR included age, gender, race, ethnicity, primary language spoken, insurance status, ZIP code, city, county, state, illness severity at time of first healthcare contact, and total number of comorbidities (TNC). (Definitions of severity, TNC, and high-risk factors are available in Appendix.) SVI scores from 2018 (available by county or census tract but not ZIP code) were assigned based on county of residence and ranged from 0 (lower vulnerability) to 1 (highest vulnerability). 33 EHR fields limited self-identification of race to White, Black/African American, Asian, American Indian/Alaska Native (AIAN), Native Hawaiian/Pacific Islander (NHPI), other, declined, or unable to answer, and ethnicity to Hispanic/Latino, not Hispanic/Latino, declined, or unable to answer. Without an option to identify race as Latino/Latinx, many patients are misclassified as White, resulting in underreporting of disparities in COVID-19 cases and mortality. 34 To be consistent with similar studies on racial disparities, we used a composite of self-reported race and ethnicity to define race categories as non-Hispanic White, Hispanic/Latinx, non-Hispanic Black, non-Hispanic Asian, non-Hispanic AIAN, non-Hispanic NHPI, non-Hispanic other/unable to answer, and non-Hispanic declined/missing data. 35 We acknowledge the inadequate representation of Middle Eastern and biracial/ multiracial identities.

Study data were obtained via the Northwestern Medicine Enterprise Data Warehouse and EHR chart review, and managed using Research Electronic Data Capture (REDCap) electronic data capture tools. 36, 37 Chi-square, t, and Mann-Whitney U tests were used to compare categorical and continuous values for patients who did and did not receive, and did and did not decline, monoclonal antibody therapy. Binary logistic regression was used for multivariable analysis modeling odds of receiving treatment. Statistical software R 4.0.3 and Stata/SE 16.0 were used for data analysis. Statistical significance was defined as p ≤ 0.05.

In order to explore geographic trends in monoclonal antibody delivery (delivery rate = patients who received treatment / all patients referred for treatment who did not decline, % delivered = delivery rate * 100) via geographic information system mapping, we focused on 181 patients residing in Cook County, Illinois. ZIP codes were geographically represented by ZIP Code Tabulation Area (ZCTA) data provided as a shapefile by census.gov based on 2020 Census data. ZCTAs are built from census tracts and represent the most frequently occurring fivedigit U.S. Postal Service ZIP code found within a given area. We grouped ZIP codes into twelve regions of Cook County to analyze data at a coarser geographic level (Appendix Figure 7 and Appendix Table 3 ). To provide additional context, we mapped census tract SVI scores from 2018 and healthcare system COVID-19 cases during the study period. Regional SVI scores were determined using average census tract SVI scores weighted by census tract population. Geographic analyses were performed with the GeoPandas package using Python 3.8.

This study was approved by the Northwestern University IRB prior to any data collection or analysis.

We reviewed 419 high-risk ambulatory adult patients with COVID-19 referred for monoclonal antibody therapy during the study period (86.9% of referrals). Sixteen patients failed to meet inclusion or met exclusion criteria. (Table 1) . Patients who were uninsured were less likely to receive treatment compared to those with private insurance (OR 0.12, 95% CI 0.02-0.45, p = 0.006). Age, total number of comorbidities, and mild or undefined illness severity were associated with increased odds of receiving treatment (OR 1.02, 95% CI 1.01-1.04, p = 0.001; OR 1.28, 95% CI 1.08-1.54, p = 0.007; OR 3.89, 95% CI 1.27-14.50, p = 0.025; OR 6.67, 95% CI 1.60-33.00, p = 0.013; respectively). Language was not statistically significantly associated with monoclonal antibody delivery.

Of the 160 patients who did not decline yet did not receive treatment, 130 patients (70.2%) had expired/canceled infusion appointments for undocumented reasons, 12 (5.9%) had symptoms for more than 10 days at time of referral, 8 (4.3%) presented to infusion appointment with severe illness/hypoxia on pre-administration assessment, 6 (2.9%) had a test more than 5 days old at time of referral, and 4 (2.2%) had severe disease at time of first healthcare contact. Compared to patients who did not decline, patients who declined treatment had a higher average county SVI score (0.70 vs. 0.57, p = 0.017), a lower average TNC (1.36 vs. 1.76, p = 0.101), and no significant difference in racial composition (p = 0.638) ( Table 2 ).

In multivariable analysis including age, race, insurance status, non-English primary language, county SVI, illness severity, and TNC, associations between receiving treatment and Hispanic/Latinx or Black race did not retain statistical significance (adjusted OR [AOR] 1.32, 95% CI 0.69-2.53, p = 0.400, and AOR 1.34, 95% CI 0.64-2.80, p = 0.439, respectively). However, patients who were uninsured or whose primary language was not English were less likely to receive treatment compared to privately insured and English-speaking patients (AOR 0.16, 95% CI 0.03-0.88, p = 0.035, and AOR 0.37, 95% CI 0.15-0.90, p = 0.028), respectively. Patients who were older or who had more comorbidities remained more likely to receive treatment (AOR 1.03, 95% CI 1.01-1.05, p = 0.004, and AOR 1.34, 95% CI 1.10-1.64, p = 0.004, respectively). Patients with mild, moderate, or undefined illness severity were also more likely to receive treatment compared to asymptomatic patients (AOR 6.24, 95% CI 1.78-21.85, p = 0.004; AOR 4.46, 95% CI 1.18-16.88, p = 0.028; and AOR 8.73, 95% CI 1.85-41.09, p = 0.006; respectively).

Patients reported addresses in 173 unique ZIP codes, including fourteen out of state. More referrals were generated from the northern suburbs of Cook County and Chicago's Central region, and higher rates of monoclonal antibody delivery were seen in the northern and western suburbs of Cook County and Chicago's Central and North Side regions, compared to Chicago's West, Southwest, and Far South Sides Table 4 ). We were unable to calculate global and local Moran's I statistics for spatial autocorrelation due to multiple ZIP codes without referrals. Higher social vulnerability exists in Chicago's West, South, and especially Southwest and Far South Sides (Fig. 2) . A bivariate chloropleth map of regional monoclonal antibody delivery and SVI revealed lower monoclonal antibody delivery rates in the more socially vulnerable West, Southwest, and Far South Sides (Fig. 3) .

During the study period, 31,066 healthcare system patients (62.8% White, 16.1% Hispanic/Latinx, 7.3% Black) residing in Cook County were diagnosed with COVID-19. More healthcare system cases were seen in the Central region and northwestern suburbs (Fig. 4) . For reference, our healthcare system patient population is approximately 42.3% White, 10.7% Hispanic/Latinx, and 6.7% Black (race/ethnicity for 37.4% of patients is unknown or not reported); the racial/ethnic demographics of Cook County, Illinois, are 42.0% White, 25.6% Hispanic/Latinx, and 23.8% Black. 38

Using the framework of race as a social construct representing structural determinants of health, we assessed disparities in monoclonal antibody delivery among high-risk ambulatory patients with COVID-19 through combined statistical and spatial analyses. In this single-center assessment of patients referred for monoclonal antibodies, Hispanic/Latinx and Black patients were less likely to receive monoclonal antibody therapy compared to White patients. After controlling for potential confounders, associations between receiving treatment and race were no longer statistically significant; instead, patients who were uninsured or whose primary language was not English were less likely to receive treatment.

Disparities in monoclonal antibody receipt were not clearly attributable to treatment refusal as patients who declined treatment were excluded from primary analysis. Of the patients who did not decline yet did not receive treatment, 18.8% no longer met clinical criteria for bamlanivimab under EUA due to illness duration or severity but were included in analysis to reflect real- world conditions. However, the remaining 81.2% had expired or canceled infusion appointments for undocumented reasons. Patients were not billed for monoclonal antibodies purchased and distributed through HHS, but we were unable to obtain information regarding the possibility of out-of-pocket infusion administration or other medication costs. None of the fourteen uninsured patients declined treatment, however, so it is unclear if cost was a concern. It is also notable that EUA patient fact sheets were available only in English and Spanish. Uninsured status and non-English primary language, however, do not encompass all of the barriers to accessing treatment, especially while ill (e.g., lack of reliable and affordable transit, paid time off, and social support); we attempted to capture some of these factors through spatial analysis and SVI. Spatial analysis demonstrated more referrals for ZIP codes with more COVID-19 cases within our healthcare system. In contrast to previously published work validating the colocalization of spatial clusters of high COVID-19 cases and high social vulnerability in Chicago, in our healthcare system, high COVID-19 cases appeared to co-localize with lower social vulnerability, suggesting that our patient population was not representative of Cook County. 25 Even so, lower were White. While our healthcare system developed a monoclonal antibody infusion program with a simple referral process and centralized appointment scheduling, delivery of this potentially life-saving treatment to socially vulnerable communities was not optimized. Our findings reinforce that unequal healthcare resource delivery reflects longstanding structural inequities at the neighborhood population level. In Chicago, factors contributing to social vulnerability follow boundaries marked by racial segregation. As such, populations at the highest risk of hospitalization and death are not afforded the best available treatments to prevent these complications of COVID-19.

Our study was limited by potential selection bias, retrospective chart review, and sample size. While monoclonal antibody referral pattern was outside the scope of this study, potentially disproportionate referrals across racial/ethnic groups could bias the racial disparities in receiving treatment. The total population of healthcare system patients eligible for monoclonal antibodies (i.e., mild to moderate cases) during the study period was not known as determination of illness severity was not uniformly captured. In addition, our sample could not account for refinements in the program as it matured. Adjustments for potential confounders were limited to demographic data available in the EHR; notably, we lacked factors contributing to socioeconomic status such as household income, education level, and healthcare worker status. Although comparison of patients who did and did not decline treatment revealed no statistically significant differences in race, insurance status, or language, relatively few patients declined treatment and we could not account for treatment hesitancy or disparate informed consent. We were unable to discern whether each patient fit the SVI demographic associated with their county apart from age, minority status, and language. Furthermore, use of county rather than census tract SVI in statistical modeling likely underestimated disparities. Geocoding, or converting addresses into geographic coordinates, should be considered for future studies. Finally, spatial statistics were limited by small sample size.

Our study's strengths and limitations highlight the need for more nuanced characterization of disparities impacting monoclonal antibody delivery. While some challenges in drug allocation and distribution to states/territories, medical centers, and finally to patients reflect the difficulties of implementing a mass infusion program, 40 our findings suggest that racial disparities in receiving treatment occur at the intersection of social determinants of health, which are defined by the physical space in which one lives.

In a pandemic that has compounded pre-existing racial inequities, examination of resource delivery offers not only insight into, but also solutions to, barriers in accessing care. Healthcare systems should strive to offer multilingual informed consent and scheduling, evening and weekend appointments, and transportation assistance. Larger medical centers can partner with community health centers to provide medication, infusion training, and on-site pharmacy. Mobile units can be deployed to rural communities and healthcare deserts to bring treatments to the community, rather than burdening vulnerable patients with the task of overcoming healthcare access hurdles. 41 Allocation models including a prioritized or reserve system for socially vulnerable communities should be further explored. 42 Finally, it is time to reprioritize universal healthcare and address the underlying structural inequities that have defined and continue to plague our nation's fragmented healthcare system.

High-risk ambulatory patients with COVID-19 who identified as Hispanic/Latinx or Black were less likely to receive monoclonal antibody therapy in univariate analysis, a finding not explained by patient refusal. Multivariable and spatial analyses suggested insurance status, language, and social vulnerability contributed to racial disparities.

The online version contains supplementary material available at https://doi.org/10.1007/s11606-022-07603-4. Figure 3 Healthcare system monoclonal antibody delivery and CDC/ATSDR Social Vulnerability Index. Bivariate chloropleth map of monoclonal antibody delivery and SVI by region. Legend (left) ascribes heat map color scales to the monoclonal antibody delivery rate (X-axis) and SVI score (Y-axis). Regions with the highest delivery rates and lowest social vulnerability are shown in dark red and regions with the lowest delivery rates and highest social vulnerability in light blue. Figure 4 Healthcare system COVID-19 cases. Total number of healthcare system patients residing in Cook County, Illinois, by ZIP code diagnosed with COVID-19 during the study period.

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. U.S. Food and Drug Administration

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of REGEN-COV TM (casirivimab and imdevimab). U.S. Food and Drug Administration

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Sotrovimab. U.S. Food and Drug Administration

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with Covid-19

Real-world experience of bamlanivimab for COVID-19: a case-control study

Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection

Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics

Uptake of outpatient monoclonal antibody treatments for COVID-19 in the United States: a cross-sectional analysis

Monoclonal antibodies are free and effective against covid-19 but few people are getting them. The Washington Post

Biden administration moves to stave off shortages of monoclonal antibodies. The Washington Post

Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19

Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

Regeneron announces U.S. government agreement to purchase additional COVID-19 antibody cocktail doses

Regeneron Pharmaceuticals 2021

Public Health Emergency. Allocation of Bamlanivimab by Jurisdiction

Department of Health & Human Services

Special Projects for Equitable and Efficient Distribution (SPEED) of COVID-19 Outpatient Therapeutics

Department of Health & Human Services

COVID-19 exacerbating inequalities in the US

Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity [Internet]. Centers for Disease Control and Infection

What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era

Large Life Expectancy Gaps in U.S. Cities Linked to Racial & Ethnic Segregation by Neighborhood

Agency for Toxic Substances and Disease Registry. CDC/ATSDR Social Vulnerability Index

Spatial inequities in COVID-19 testing, positivity, confirmed cases, and mortality in 3 U.S. cities: an ecological study

Association between social vulnerability and a county's risk for becoming a COVID-19 hotspot -United States

Social vulnerability and racial inequality in COVID-19 deaths in Chicago

Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: efficacy, ethnic and racial disparities

Racial and ethnic disparities in receipt of medications for treatment of COVID-19 -United States

Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bebtelovimab. U.S. Food 5 and Drug Administration

COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab. U.S. Food and Drug Administration

Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry/Geospatial Research

How Many Chicago Latinos Have Died From COVID-19? There Are No Up-To-Date Numbers. WBEZ Chicago

Alternative methods for grouping race and ethnicity to monitor COVID-19 outcomes and vaccination coverage

The REDCap consortium: building an international community of software platform partners

Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support

American Community Survey 5-Year Data Profile Demographic and Housing Estimates

FDA experts discuss COVID-19 therapeutic clinical trials

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities

A novel approach to equitable distribution of scarce therapeutics: institutional experience implementing a reserve system for allocation of COVID-19 monoclonal antibodies